Drug Shortage Report for MYLAN-GABAPENTIN
Report ID | 7020 |
Drug Identification Number | 02397498 |
Brand name | MYLAN-GABAPENTIN |
Common or Proper name | GABAPENTIN |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | GABAPENTIN |
Strength(s) | 800MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 100BT |
ATC code | N03AX |
ATC description | ANTIEPILEPTICS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2017-04-11 |
Estimated end date | |
Actual end date | 2017-08-23 |
Shortage status | Resolved |
Updated date | 2017-08-24 |
Company comments | Discontinuation reported under ID 20175. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2017-08-24 | French | Compare |
v5 | 2017-08-24 | English | Compare |
v4 | 2017-05-05 | French | Compare |
v3 | 2017-05-05 | English | Compare |
v2 | 2017-04-13 | French | Compare |
v1 | 2017-04-13 | English | Compare |
Showing 1 to 6 of 6